Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
The small-molecule oncology player zeroes in on its first commercial opportunity.
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
Over the past decade Roche and Novartis consistently spent more on R&D than other big pharma groups, while Abbvie and Astrazeneca have added to their budgets.
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
The Vitrakvi follow-on LOXO-195 yields results backing both the rationale behind its development and Bayer’s decision to take on full rights.